Navigation Links
Global miRNA Market Outlook to 2018
Date:12/24/2013

NEW YORK, Dec. 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global miRNA Market Outlook to 2018

http://www.reportlinker.com/p01929534/Global-miRNA-Market-Outlook-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

The recent discovery of miRNA and its wide applicability have sparked off a lot of interest among researchers as well as commercial players. Owing to the same, there are numerous clinical trials being organized all over the world in order to assess the potential of miRNA in diverse fields such as Cancer, Asthma, Heart disorders, Diabetes, Hepatitis etc. The report, "Global miRNA Market Outlook to 2018" provides an in-depth analysis of the various aspects of miRNA at the industry as well as the research front.

The market has been divided into three sections i.e., The Americas, Europe and Asia Pacific. These regions have then been analyzed to draw patterns in terms of research areas and applicability. A brief look at the market suggests that cancer is the most researched topic and regions such as United States, United Kingdom, France, Israel and China are the major players interested in evaluating the role played by miRNA.

Most of the current research is focused on utilizing miRNA for diagnostic purposes such as expression profiling, response evaluation and setting potential biomarkers in diseases. Anoth
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today ... Financial Officer has resigned.  The Company has hired ... retired in December 2014, as full time interim CFO ... Andy Ashworth began his employment ... smooth transition.  Andy was the Company,s CFO from September ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... RALEIGH, N.C., April 3, 2008 Campbell Alliance, ... and,biotech industries, today announced that its Managed Markets ... Bio/Pharmaceutical Forum on Effective,Product Pricing and Modeling Strategies ... conference will be held on April 10 through ...
... April 3, 2008 Dendreon Corporation,(Nasdaq: DNDN ) ... with an institutional investor to sell 8.0 million shares ... 8.0 million shares of its,common stock for gross proceeds ... estimated offering expenses, in a,"registered direct" offering. The investor ...
... Offering Broad Array of Healthcare Products to ... with Immune Deficiency and Bleeding Disorders, OTTAWA, ... today,announced that Canadian Blood Services, and Hema-Quebec, have ... (Antihemophilic Factor,[Recombinant]), Humate(R) P (Antihemophilic factor / von ...
Cached Biology Technology:Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 2Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 3Dendreon Announces $47 Million Registered Direct Offering 2Dendreon Announces $47 Million Registered Direct Offering 3CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 2CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 3CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 4CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 5CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 6CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 7CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 8
(Date:7/31/2015)... 31, 2015 The 10 th International Conference ... BGI from October 22-25, 2015, in Shenzhen , ... is celebrating its 10 th anniversary this year. Since its ... most influential annual meetings in the ,omics, fields, and is ... ICG-10 focuses on recent breakthroughs and advances ...
(Date:7/23/2015)... 23, 2015 Aware, Inc. (NASDAQ: AWRE ), ... financial results for its second quarter ended June 30, 2015.  ... was $4.5 million, a decrease of 33% compared to $6.8 ... the second quarter of 2015 was $0.3 million, or $0.01 ... per diluted share, in the same period a year ago.  ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... of building a complete, functional, artificial cell. Though this ... many are making progress on various fronts. Prof. Roy ... Material,s and Interfaces Department recently took a significant step ... system on a glass chip. This system, composed of ...
... Researchers Robert Hoare ( Landcare Research , New Zealand) and Erik ... moths after the Minotaur of Greek mythology and the ... of southern pigmy moths . The study was published in ... tiny moths, with wingspans of 3 to 8 millimetres, belong to ...
... the functions of the three enzymes Tan, Ebony and Black ... in neurotransmitter recycling for the visual process. RUB researchers from ... flies cannot see without this recycling. Their analysis of the ... Anna Ziegler, Florian Brsselbach and Bernhard Hovemann report in the ...
Cached Biology News:Cell on a chip reveals protein behavior 2Tiny minotaurs and mini-Casanovas: Ancient pigmy moths reveal secrets of their diversity 2Blind flies without recycling 2Blind flies without recycling 3
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
... activated ,• Eliminates nonspecific products due ... Excellent specificity allows extension through DNA regions ... Leaves an 'A' overhang ,TEMPase ... GeneChoice DNA Polymerase that remains inactive ...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... Probes is pleased to offer the ... ultrasensitive detection of primary amines. Developed ... University, the ATTO-TAG reagents are similar ... naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, all of ...
Biology Products: